CompletedPHASE1, PHASE2NCT06051448
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
Studying MELAS
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Philadelphia
- Principal Investigator
- Elizabeth M McCormick, MSChildren's Hospital of Philadelphia
- Intervention
- Promoting Resilience in Stress Management (PRISM)(behavioral)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Collaborators
North American Mitochondrial Disease Consortium (NAMDC) · National Institute of Neurological Disorders and Stroke (NINDS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06051448 on ClinicalTrials.govOther trials for MELAS
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06961344An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)Tisento Therapeutics
- RECRUITINGPHASE2NCT06644534A Study to Assess TTI-0102 vs Placebo in MELAS PatientsThiogenesis Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT06402123A Phase 2b Study of Zagociguat in Patients With MELASTisento Therapeutics